1143P Nivolumab and ipilimumab (N+I) is active in patients (pts) with metastatic uveal melanoma (mUM) with extra-hepatic only involvement: Pooled analysis from 2 phase II trials

Abstract

Background: There is no standard treatment for mUM. A high-throughput genomic and transcriptomic program was initiated to uncover potential targets and assign molecularly guided treatment to this "hard-to-treat" tumor.Methods: From March 2016 to November 2019 mUM patients were included in the prospective Treat20Plus study and tumor was analyzed via a comprehensive molecular tumor analysis program. A molecular tumor board interpreted the data and issued treatment recommendations.

Immuno-oncology approaches in uveal melanoma: tebentafusp and beyond

“… 5 , 47 A pooled analysis compared patients with mUM treated with IpiNivo with matched historical controls. 48 In patients with extrahepatic disease only, IpiNivo was associated with survival >3.2 times longer than historical treatments, suggesting that this subgroup derived benefit from IpiNivo. 48 However, in patients with hepatic disease, there was no difference in survival between treatments.…”

“… 48 In patients with extrahepatic disease only, IpiNivo was associated with survival >3.2 times longer than historical treatments, suggesting that this subgroup derived benefit from IpiNivo. 48 However, in patients with hepatic disease, there was no difference in survival between treatments. Another retrospective cohort of 178 ICI-treated patients supported these findings; patients with extrahepatic metastases trended to longer OS than patients with hepatic metastases only (18.2 versus 6.1 months, P = 0.07).…”

Tebentafusp: a first-in-class treatment for metastatic uveal melanoma

“… 29 Interestingly, an analysis of outcomes for patients on the two ipilimumab/nivolumab phase II studies compared to matched historical controls treated implied that the only patients who have benefit from this combination are the rare group of UM patients who have disease limited to extra-hepatic sites. 49 …”